Bacterial agents causing meningitis during 2013-2014 in Turkey: A multi-center hospital-based prospective surveillance study

Autor: Yasemin Ozsurekci, Zafer Kurugöl, Hasan Tezer, Fatih Yilmaz, Ünal Uluca, Rengin Şiraneci, Diyar Tamburaci, Ümit Çelik, Gulnar Sensoy, Ahu Kara, Mehmet Ceyhan, Yildiz Camcioglu, Nilden Tuygun, Nezahat Gürler, Aslınur Özkaya Parlakay, Metehan Ozen, Nuran Salman, Ener Cagri Dinleyici, Necdet Kuyucu, Melda Celik, Eda Karadag Oncel, Sefika Elmas Bozdemir, Aybüke Akaslan, Melike Emiroglu, Emre Alhan, Fatmanur Öz, Ümmühan Çay, Fatih Akin, Adem Karbuz, Nevin Hatipoğlu, Solmaz Celebi, Nurşen Belet, Tolga İnce, İlker Devrim, Enes Coskun, Mustafa Hacimustafaoglu
Přispěvatelé: OMÜ, Ege Üniversitesi, Çukurova Üniversitesi, İç Hastalıkları, Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı., Hacımustafaoğlu, Mustafa, Çelebi, Solmaz, Selçuk Üniversitesi
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Male
Pediatrics
Turkey
Bacterial meningitis
W135 meningococcal disease
Neisseria meningitidis
0302 clinical medicine
Bacterium
Observational study
Epidemiology
Pathology
Immunology and Allergy
030212 general & internal medicine
Child
Children
Vaccines
Epidemiological monitoring
Incidence
Hospital based
Classification
Research Papers
Multicenter study
Polymerase chain reaction
Hospitalization
Clinical trial
ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS
Neisseria-meningitidis
hospital surveillance
Female
epidemiology
InformationSystems_MISCELLANEOUS
Meningitis
Human
Adult
medicine.medical_specialty
Surveillance study
Adolescent
Child
preschool
Fever
Immunology
Microbiology
Article
03 medical and health sciences
030225 pediatrics
medicine
Humans
Prospective study
Intensive care medicine
Meningitis
bacterial
Pharmacology
etiologic agents
Bacteria
business.industry
ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS
Infant
medicine.disease
Nonhuman
Mycoplasma pneumoniae
ComputingMethodologies_PATTERNRECOGNITION
Meningococcosis
Serotype
Neisseria Meningitidis
Preschool child
Isolation and purification
Biotechnology & Applied Microbiology
Immunization
School child
business
Prospective studies
Meta analysis
ISSN: 0003-8873
Popis: WOS: 000388736900040
PubMed: 27454468
This is an observational epidemiological study to describe causes of bacterial meningitis among persons between 1 month and 18 y of age who are hospitalized with suspected bacterial meningitis in 7 Turkish regions. covering 32% of the entire population of Turkey. We present here the results from 2013 and 2014. A clinical case with meningitis was defined according to followings: any sign of meningitis including fever, vomiting, headache, and meningeal irritation in children above one year of age and fever without any documented source, impaired consciousness, prostration and seizures in those < 1 y of age. Single tube multiplex PCR assay was performed for the simultaneous identification of bacterial agents. The specific gene targets were ctrA, bex, and ply for N. meningitidis, Hib, and S. pneumoniae, respectively. PCR positive samples were recorded as laboratory-confirmed acute bacterial meningitis. A total of 665 children were hospitalized for suspected acute meningitis. The annual incidences of acute laboratory-confirmed bacterial meningitis were 0.3 cases / 100,000 population in 2013 and 0.9 cases/100,000 in 2014. Of the 94 diagnosed cases of bacterial meningitis by PCR, 85 (90.4%) were meningococcal and 9 (9.6%) were pneumococcal. Hib was not detected in any of the patients. Among meningococcal meningitis, cases of serogroup Y, A, B and W-135 were 2.4% (n = 2), 3.5% (n = 3), 32.9% (n = 28), and 42.4% (n = 36). No serogroup C was detected among meningococcal cases. Successful vaccination policies for protection from bacterial meningitis are dependent on accurate determination of the etiology of bacterial meningitis. Additionally, the epidemiology of meningococcal disease is dynamic and close monitoring of serogroup distribution is comprehensively needed to assess the benefit of adding meningococcal vaccines to the routine immunization program.
GlaxoSmithKline Biologicals SAGlaxoSmithKline
Funding for this study was provided by GlaxoSmithKline Biologicals SA. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of this manuscript for factual accuracy but the authors are solely responsible for final content and interpretation. The authors received no financial support or other form of compensation related to the development of the manuscript.
Databáze: OpenAIRE
Externí odkaz: